Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
This is a unique seminar with the Olav Thon Foundation's International Research Awardees for Mathematics and Natural Science and Medicine 2017.
The first talk will be held by International Research Prize winner Jan Hoeijmakers from Erasmus University Rotterdam, who is one of the most significant scientists in molecular genetics of our time.
Further talks will be held by Research Awardee Mahmood Amiry-Moghaddam on Parkinson's disease, and by Research Awardees Henrik Zetterberg and Nenad Bogdanovic on Alzheimer research.
Time and place: March 2nd, 2017 12:00 PM - 03:00 PM, Runde Auditorium R-105 at Domus Medica, Gaustad
Deadline for registration: February 23rd
Sports play an important role in our society. Four Norwegian researchers, two from OUS, have published an article in EMBO reports where they discuss problems occurring in the testing of athletes for doping.
The authors (E. Boye and T. Skotland from OUS (photo), J. Nissen-Meyer from UiO and B. Østerud, UiTø) describe how the World Antidoping Agency (WADA) pretends never to make mistakes and is resistant to any form of discussion with other scientists. This attitude creates false positives and athletes are being sanctioned while innocent, with dramatic consequences for the individual. It is argued that both the technological, ethical and legal procedures should be revised and an independent body should monitor the function of WADA.
Findings from Rusten group published in Nature on microenvironmental autophagy draw nationwide attention
Nadja Katheder and collaborators in the lab of Tor Erik Rusten, the Department of Molecular Cell Biology, and CCB has published an article entitled "Microenvironmental autophagy supports tumor growth", in an advanced online publication 11th of January in the journal Nature (journal impact factor 41.46).
The findings have been subject to news coverage by the Norwegian national broadcasting corporation (NRK).
The prestigious journal "Developmental Cell" has recently published an article in their "Previews" section, entitled "Breaking Down Neighbors to Fuel Tumorigenesis". Here, the authors discuss how the work of Katheder and colleagues "opens new avenues for understanding and manipulating cancers through cell-cell communication."
"Science" article from Johanna Olweus's group highlighted by editorial in New England Journal of Medicine
The article "Targeting of cancer neoantigens with donor-derived T cell receptor repertoires" by Erlend Strønen et al, published in Science in June 2016, is highlighted by an editorial in the "Clinical Implications of Basic Research" section in the Feb 2nd edition of New England Journal of Medicine.
The editorial is entitled "The Antigenicity of the Tumor Cell — Context Matters".
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".
For the month of January 2017, this honour went to Theis Tønnessen, leader of the "Genetics of autoimmunity and cancer" group at the Department of Medical Genetics at the Division of Diagnostics and Intervention, Oslo University Hospital.
Every year 16.000 Norwegians are stricken with stroke, and more than 60.000 have previously had one or more strokes. It is therefore important that the foremost Norwegian experts in the field gather in order and be updated on what is new within preventive, acute treatment and rehabilitation from stroke.
David Russell from the Department of Neurology at the Division of Surgery and Clinical Neuroscience at Oslo University Hospital welcomes participants to the 6th national conference on stroke - "den 6. Nasjonale konferanse om Hjerneslag".
The Norwegian Radium Hospital Research Foundation will also for 2017 distribute resources to photodynamic therapy and photochemical internalization (PDT/PCI) related research. In 2016 various research projects within this field were founded with a total of NOK 1,79 million. Employees at the Oslo University Hospital are welcome to apply.
The closing date for applications is February 28th, 2017.
Oslo University Hospital hereby announce research awards in the following two catagories for 2017:
- Excellent Researcher Award (one prize, 300.000 NOK)
- Early Career Award (two prizes of 150.000 NOK each)
The candidate must be employed by Oslo University Hospital or University of Oslo, and be a member of a research group at Oslo University Hospital/University of Oslo.
New insight into the origin of disseminated tumor cells in breast cancer published in Genome Biology
Elen Kristine Møller, postdoc at the Department of Cancer Genetics, studied during her PhD project the fate of disseminated tumor cells (DTCs). In a collaborative study among OUS, University of Chicago, University of Leuven and the Francis Crick Institute it is revealed that breast cancer cells break away and spread to other parts of the body relatively late on in breast tumor development.
The findings are published in the December 9th issue of Genome Biology (journal impact factor 11.3), in an article entitled "Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing".
Update: The story has become the "Editors Choice" in the January 4th issue of Science Translational Medicine.
The Norsk Hydro’s Fund for Cancer Research Lecture January 16th 10:45 - 12:00 in the Auditorium (K-building) at Montebello will be held by the prominent scientist Channing J. Der from UNC Lineberger Comprehensive Cancer Center, Chapel Hill.
Title of his talk:
"Drugging undruggable RAS for cancer treatment"
Dr. Channing J. Der is recognized internationally for his contribution to the discovery and research of the Ras family of oncoproteins.
Early phase drug development: From idea to concept
Feb 3, 2017
Feb 2, 2017
Oncolytic peptide LTX-315; the road from basic science to clinical trials
Jan 26, 2017
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
Cancer and neurodegeneration: Time to move beyond Janus?
Neurology (in press)
The Glucocorticoid-Induced Leucine Zipper Gene (GILZ) Expression Decreases after Successful Treatment of Patients with Endogenous Cushing's Syndrome and May Play a Role in Glucocorticoid-Induced Osteoporosis
Endocr Rev, 30 (7), 932
More selected publications